Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-012448510-5/50164-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Trial of a GPIIb/IIIa Platelet Receptor Blocker in Refractory Unstable Angina

  1994cited by this paper
• Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty).

  1993cited by this paper
• Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group.

  1993cited by this paper
• Long-term outcome following successful reopening of abrupt closure after coronary angioplasty.

  1993cited by this paper
• Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty

  1993cited by this paper
• Does the AHA/ACC task force grading system predict outcome in multivessel coronary angioplasty?

  1992cited by this paper
• Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile.

  1992cited by this paper
• The declining risk of post-transfusion hepatitis C virus infection.

  1992cited by this paper
• A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators.

  1992cited by this paper
• Transmission of Retroviruses from Seronegative Donors by Transfusion during Cardiac Surgery

  1992cited by this paper
• The risk of transfusion-transmitted infection.

  1992cited by this paper
• Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis.

  1991cited by this paper
• Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.

  1991cited by this paper
• Release of creatine kinase-MB and cardiac specific troponin-I following percutaneous transluminal coronary angioplasty.

  1991cited by this paper
• Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty.

  1991cited by this paper
• Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials.

  1990cited by this paper
• Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty.

  1990cited by this paper
• Unstable angina and coronary angioplasty.

  1990cited by this paper
• Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management.

  1989cited by this paper
• Adequate heparinization during PTCA: assessment using activated clotting times.

  1989cited by this paper
• Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications

  1989cited by this paper
• Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.

  1988cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

  1988cited by this paper
• Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty.

  1988cited by this paper
• Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.

  1987cited by this paper
• Changes in myoglobin, creatine kinase and creatine kinase-MB after percutaneous transluminal coronary angioplasty for stable angina pectoris.

  1987cited by this paper
• Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty.

  1987cited by this paper
• Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.

  1987cited by this paper
• Paucity of subtle myocardial injury after angioplasty delineated with MB CK.

  1986cited by this paper
• Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor.

  1985cited by this paper
• A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.

  1985cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis

  2019cites this paper
• Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI

  2018cites this paper
• Impact of Antiplatelet Therapy and Platelet Reactivity Testing on Cardiovascular Outcomes in Patients with Chronic Kidney Disease

  2017cites this paper
• 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report

  2017cites this paper
• Glycoprotein IIb/IIIa Antagonists

  2017cites this paper
• Current Concepts of Pathogenesis and Treatment

  2016cites this paper
• A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.

  2016cites this paper
• Overview, Measurement and Point-of-Care Testing of Platelet Function

  2016cites this paper
• Safety and predictors of same day discharge after elective percutaneous coronary intervention

  2015cites this paper
• Eptifibatide in coronary intervention: past time for the next chapter.

  2015cites this paper
• Comparative Effectiveness and Safety of a Catheterization Laboratory–Only Eptifibatide Dosing Strategy in Patients Undergoing Percutaneous Coronary Intervention

  2015cites this paper
• Coronary artery bypass grafting versus percutaneous intervention in coronary revascularization: a historical perspective and review

  2015cites this paper
• American College of Chest Physicians Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery

  2015cites this paper
• Segurança e preditores de sucesso da alta hospitalar no mesmo dia após intervenção coronária percutânea eletiva

  2015cites this paper
• Coronary Artery Bypass Surgery and Percutaneous Coronary Revascularization: Impact on Morbidity and Mortality in Patients with Coronary Artery Disease

  2015cites this paper
• Medical Treatment of Unstable Angina and Acute Non-ST-Elevation Myocardial Infarction

  2015cites this paper
• Bolus - only versus bolus followed by infusion of glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention

  2015cites this paper
• Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2014cites this paper
• Statistical Approaches to Improving Trial Efficiency and Conduct

  2014cites this paper
• Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome

  2014cites this paper
• Antiplatelet Drugs in the Management of Cardiovascular Indications

  2014cites this paper
• Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register

  2014cites this paper
• Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention

  2014cites this paper
• Triple Antiplatelet Therapy in Acute Coronary Syndrome in 2014

  2014cites this paper
• Eptifibatide-induced acute profound thrombocytopenia: a case report

  2014cites this paper
• Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors

  2014cites this paper
• and Societal Perspective

  2014cites this paper
• Antiplatelet medications and evolving antithrombotic medication

  2013cites this paper
• Integrin Antagonists and Angiogenesis

  2013cites this paper
• Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

  2013cites this paper
• Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.

  2013cites this paper
• Imaging or trusting on surface anatomy? A comparison between fluoroscopic guidance and anatomic landmarks for femoral artery access in diagnostic cardiac catheterization. A randomized control trial

  2013cites this paper
• Evidence-Based Clinical Practice Guidelines American College of Chest Physicians and Prevention of Thrombosis, 9th ed: Antiplatelet Drugs : Antithrombotic Therapy

  2012cites this paper
• Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  2012cites this paper
• Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study

  2012cites this paper
• Novel Antiplatelet Therapies

  2012cites this paper
• Glycoprotein IIb/IIIa antagonists.

  2012cites this paper
• TRANSRADIAL ACCESS FOR PCI: A NOVEL APPROACH / CHANGING TRENDS OF VASCULAR ACCESS

  2012cites this paper
• Cardiovascular Angiography and Interventions Association Task Force on Practice Guidelines and the Society for Report of the American College of Cardiology Foundation/American Heart 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A

  2012cites this paper
• Stenting in Acute STEMI Intervention.

  2012cites this paper
• Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates

  2012cites this paper
• Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Parenteral Anticoagulants : Antithrombotic

  2012cites this paper
• Platelet Glycoprotein IIb/IIIa Receptor Antagonists

  2012cites this paper
• Economic Value of Thrombolysis with Adjunctive Abciximab in Patients with Subacute Peripheral Arterial Occlusion

  2012cites this paper
• Intravascular ultrasound findings that are predictive of no reflow after percutaneous coronary intervention for saphenous vein graft disease.

  2012cites this paper
• Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non-ST-Segment Elevation Acute Coronary Syndromes

  2012cites this paper
• on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions the American College of Cardiology Foundation/American Heart Association Task Force 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A Report of

  2012cites this paper
• The Management of Thrombotic Lesions in the Cardiac Catheterization Laboratory

  2012cites this paper
• Qualité de vie et artériopathie des membres inférieurs

  2012cites this paper
• Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors

  2012cites this paper
• Antiplatelet agents in ischemic heart disease.

  2012cites this paper
• Impact of Abciximab in Elderly Patients with High-Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

  2011cites this paper
• Strategia leczenia abciksimabem u pacjentów z ostrymi zespołami wieńcowymi. Analiza przesłanek teoretycznych i wyników badań klinicznych

  2011cites this paper
• Aggregation and Coronary Thrombosis Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Modifiable risk factors for vascular access site complications in the IMPACT II

  2011cites this paper
• abciximab therapy Occurrence and clinical significance of pseudothrombocytopenia during

  2011cites this paper
• Intracranial Hemorrhage Following Neuroendovascular Procedures with Abciximab is Associated with High Mortality: A Multicenter Series

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• Management of bleeding complications in the anticoagulated patient.

  2011cites this paper
• Intracoronary Compared to Intravenous Abciximab in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention Reduces Mortality, Target Vessel Revascularization and Reinfarction after 1 Year

  2011cites this paper
• Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.

  2011cites this paper
• the Society for Cardiovascular Angiography and Interventions Foundation/American Heart Association Task Force on Practice Guidelines and Executive Summary : A Report of the American College of Cardiology 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:

  2011cites this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• Safety evaluation of tirofiban

  2010cites this paper
• Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy

  2010cites this paper
• Randomized, double‐blind comparison of effects of abiciximab bolus only vs. on‐label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting

  2010cites this paper
• Integrins as therapeutic targets: lessons and opportunities

  2010cites this paper
• Nuevas evidencias y directrices en antiagregación y anticoagulación en síndrome coronario agudo e intervencionismo coronario percutáneo

  2010cites this paper
• Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy

  2010cites this paper
• Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).

  2010cites this paper
• Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.

  2010cites this paper
• Monitoring of Antithrombotic Therapies in Interventional Cardiology

  2010cites this paper
• Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial.

  2010cites this paper
• The PFA-100® cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations

  2010cites this paper
• Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome

  2010cites this paper
• Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome

  2010cites this paper
• A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice

  2010cites this paper
• Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction

  2010cites this paper
• Unfractionated Heparin and Enoxaparin for the Management of Non-ST-Segment Elevation Acute Coronary Syndromes

  2010cites this paper
• Undetected acute aortic dissection in a patient referred for primary coronary angioplasty: a successful treatment of perioperative bleeding after abciximab administration

  2010cites this paper
• Long‐Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention

  2010cites this paper
• Basic principles of platelet biology and clinical implications.

  2010cites this paper
• Late outcomes following percutaneous coronary interventions: results from a large, observational registry.

  2010cites this paper
• Estudio aleatorizado con abciximab o eptifibatide en angioplastia coronaria compleja. Resultados intrahospitalarios y a 30 dias

  2010cites this paper
• Management of patients with unstable angina/non-ST-elevation myocardial infarction: a critical review of the 2007 ACC/AHA guidelines

  2009cites this paper
• Impact of bleeding complications on outcomes after percutaneous coronary interventions

  2009cites this paper
• Platelet Glycoprotein IIb/IIIa Receptor Blockade in Primary Coronary Intervention

  2009cites this paper
• Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.

  2009cites this paper
• Invasive Coronary Imaging

  2009cites this paper
• Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.

  2009cites this paper
• Leukocyte integrins and their ligand interactions

  2009cites this paper
• Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment

  2009cites this paper
• Long term efficacy of abciximab bolus‐only compared to abciximab bolus and infusion after transradial coronary stenting

  2009cites this paper
• Abciximab (ReoPro)-Induced Thrombocytopenia Diagnosed Through Measurement of Heparin-Dependent Antibody

  2009cites this paper
• Abciximab: a review and update for clinicians

  2008cites this paper
• Rescue Treatment with Intra-arterial Tirofiban Infusion and Emergent Carotid Stenting

  2008cites this paper
• Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Allergen-Induced Inflammation

  2008cites this paper
• Percutaneous coronary intervention and the use of glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease on dialysis: A single center experience

  2008cites this paper
• Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.

  2008cites this paper